Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2
News 08.07.2021 ZURICH-SCHLIEREN, Switzerland, July 08, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today reported on the clinical progress of its novel antiviral candidate, ensovibep,...